REFERENCES
Taffet SL, Das KM: Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci 28:833–842, 1983
Azad Khan AK, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2:892–895, 1977
Prakash A, Markham A: Oral delayed-release mesalazine: A review of its use in ulcerative colitis and Crohn's disease. Drugs 57:383–408, 1999
Clemett D, Markham A: Prolonged-release mesalazine: A review of its therapeutic potential in ulcerative colitis and Crohn's disease. Drugs 59:929–956, 2000
Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625–1629, 1987
Sninsky CA, Cort DH, Shanahan F, Powers BJ, Sessions JT, Pruitt RE, Jacobs WH, Lo SK, Targan SR, Cerda JJ: Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study [see comments]. Ann Intern Med 115:350–355, 1991
Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M: Mesalamine capsules for treatment of active ulcerative colitis: Results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 88:1188–1197, 1993
Hetzel DJ, Shearman DJ, Labrooy J, Bochner F, Imhoff DM, Gibson GE, Fitch RJ, Hecker R, Rowland R: Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scand J Gastroenterol Suppl 148:61–69, 1988
Feurle GE, Theuer D, Velasco S, Barry BA, Wordehoff D, Sommer A, Jantschek G, Kruis W: Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: A randomised double blind trial. Gut 30:1354–1361, 1989
Zinberg J, Molinas S, Das KM: Double-blind-placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol 85:562–566, 1990
Sutherland L, Robinson M, Onstad G, Peppercorn M, Greenberger N, Goodman M, Martin F: A double-blind, placebo-controlled, multicentre stuy of the efficacy and safety of 5-aminosalicylic acid tablets in the treatment of ulcerative colitis. Can J Gastroenterol 4:463–467, 1990
Sutherland LR, May GR, Shaffer EA: Sulfasalazine revisited: A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis [see comments]. Ann Intern Med 118:540–549, 1993
Sutherland L, Roth D, Beck P, May G, Makiyama K: Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Syst Rev Issue 3, 2000
Munakata A, Yoshida Y, Muto T, Tsuchiya S, Fukushima T, Hiwatashi N, Kobayashi K, Kitano A, Shimoyama T, Inoue M: Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. J Gastroenterol 30(suppl 8):108–111, 1995
Fleig WE, Laudage G, Sommer H, Wellmann W, Stange EF, Riemann J: Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion 40:173–180, 1988
Willoughby CP, Cowan RE, Gould SR, Machell RJ, Stewart JB: Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis. Scand J Gastroenterol Suppl 148:40–44, 1988
Rao SS, Dundas SA, Holdsworth CD, Cann PA, Palmer KR, Corbett CL: Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. Gut 30:675–679, 1989
Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA: Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 29:669–674, 1988
Rachmilewitz D: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ 298:82–86, 1989
Robinson M, Hanauer S, Hoop R, Zbrozek A, Wilkinson C: Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther 8:27–34, 1994
Meyers S, Sachar DB, Present DH, Janowitz HD: Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology 93:1255–1262, 1987
Riley SA. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut 42:761–763, 1998
Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, Hodgson HJ, Parkins KJ, Taylor MD: Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group [see comments]. Gastroenterology 114:15–22, 1998
Kruis W, Brandes JW, Schreiber S, Theuer D, Krakamp B, Schutz E, Otto P, Lorenz-Mayer H, Ewe K, Judmaier G: Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis [see comments]. Aliment Pharmacol Ther 12:707–715, 1998
Miner P, Hanauer S, Robinson M, Schwartz J, Arora S: Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci 40:296–304, 1995
Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF: A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. Gastroenterology 112:718–724, 1997
Sandberg-Gertzen H, Jarnerot G, Kraaz W: Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology 90:1024–1030, 1986
Wright JP, O'Keefe EA, Cuming L, Jaskiewicz K: Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig Dis Sci 38:1837–1842, 1993
Hanauer S, Sninsky C, Robinson M, Powers B, McHattie J, Mayle J, et al: An oral preparation of mesalamine as longterm maintenance therapy for ulcerative colitis. A randamized, placebo-controlled trial. Ann Intern Med 124:204–211, 1996
Ardizzone S, Petrillo M, Imbesi V, Cerutti R, Bollani S, Bianchi Porro G: Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther 13:373–379, 1999
Sutherland L, Roth D, Beck P, May G, Makiyama K: Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis. Cochrane Database Syst Rev Issue 3, 2000
Dew MJ, Hughes P, Harries AD, Williams G, Evans BK, Rhodes J: Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J (Clin Res Ed) 285:1012, 1982
Dew MJ, Harries AD, Evans N, Evans BK, Rhodes J: Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. Br Med J (Clin Res Ed) 287:23–24, 1983
Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA: Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 94:1383–1389, 1988
Mulder CJ, Tytgat GN, Weterman IT, Dekker W, Blok P, Schrijver M, van der Heide H: Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis [see comments]. Gastroenterology 95:1449–1453, 1988
McIntyre PB, Rodrigues CA, Lennard-Jones JE, Barrison IG, Walker JG, Baron JH, Thornton PC: Balsalazide in the maintenance treatment of patients with ulcerative colitis, a doubleblind comparison with sulphasalazine. Aliment Pharmacol Ther 2:237–243, 1988
Ireland A, Mason C, Jewell D: Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut 29:835–837, 1988
Kiilerich S, Ladefoged K, Rannem T, Ranlov PJ: Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group. Gut 33:252–255, 1992
Rijk MC, van Lier HJ, van Tongeren JH: Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: A prospective, doubleblind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group. Am J Gastroenterol 87:438–442, 1992
Nilsson A, Danielsson A, Lofberg R, Benno P, Bergman L, Fausa O, Florholmen J, Karvonen AL, Kildebo S, Kollberg B: Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. Am J Gastroenterol 90:381–387, 1995
Rutgeerts P: Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. Aliment Pharmacol Ther 3: 183–191, 1989
Ardizzone S, Petrillo M, Molteni P, Desideri S, Bianchi Porro G: Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. J Clin Gastroenterol 21:287–289, 1995
Fernandez-Bañares F, Hinojosa J, Sanchez-Lombrana JL, Navarro E, Martinez-Salmeron JF, Garcia-Puges A, Gonzalez-Huix F, Riera J, Gonzalez-Lara V, Dominguez-Abascal F, Gine JJ, Moles J, Gomollon F, Gassull MA: Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 94:427–433, 1999
Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11:853–858, 1997
Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial [see comments]. Lancet 354:635–639, 1999
Fockens P, Mulder CJ, Tytgat GN, Blok P, Ferwerda J, Meuwissen SG, Tuynman HA, Dekker W, Gasthuis K, van Hees PA: Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group [see comments]. Eur J Gastroenterol Hepatol 7:1025–1030, 1995
Giaffer MH, Holdsworth CD, Lennard-Jones JE, Rodrigues CA, McIntyre PB, Manjunatha S, Baron JH, Barrison IG, Polson RJ, Hoare AM: Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther 6:479–485, 1992
Green JR, Swan CH, Rowlinson A, Gibson JA, Brown P, Kerr GD, Swarbrick ET, Thornton P: Short report: Comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 6:647–652, 1992
Travis SP, Tysk C, de Silva HJ, Sandberg-Gertzen H, Jewell DP, Jarnerot G: Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 35:1282–1286, 1994
Courtney MG, Nunes DP, Bergin CF, O'Driscoll M, Trimble V, Keeling PW, Weir DG: Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis [see comments]. Lancet 339:1279–1281, 1992
Green JR, Gibson JA, Kerr GD, Swarbrick ET, Lobo AJ, Holdsworth CD, Crowe JP, Schofield KJ, Taylor MD: Maintenance of remission of ulcerative colitis: A comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment Pharmacol Ther 12:1207–1216, 1998
Ngo Y, Gelinet JM, Ivanovic A, Kac J, Schenowitz G, Vilotte J, Rambaud JC: Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double-blind versus placebo randomized trial. (In French) Gastroenterol Clin Biol 16:782–786, 1992
Williams CN, Haber G, Aquino JA: Double-blind, placebocontrolled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories. Dig Dis Sci 32:71S–75S, 1987
Campieri M, De Franchis R, Bianchi Porro G, Ranzi T, Brunetti G, Barbara L: Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol 25:663–668, 1990
Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tampieri M, Iannone P, Brunetti G, Miglioli M, Barbara L: Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial. Int J Colorectal Dis 5:79–81, 1990
Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tampieri M, Iannone P, Miglioli M, Barbara L: Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 32:929–931, 1991
Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L: 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92:1894–1898, 1987
Campieri M, Gionchetti P, Belluzzi A: Sucralfate, 5-aminosalicylic acid, and placebo enemas in the treatment of distal ulcerative colitis. Eur J Gastroenterol Hepatol 3:41–44, 1991
Hanauer SB: Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The US Pentasa Enema Study Group. Inflamm Bowel Dis 4:79–83, 1998
Marshall JK, Irvine EJ: Rectal aminosalicylate therapy for distal ulcerative colitis: A meta-analysis. Aliment Pharmacol Ther 9:293–300, 1995
Farup PG, Hovde O, Halvorsen FA, Raknerud N, Brodin U: Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens. Scand J Gastroenterol 30:164–170, 1995
Lee FI, Jewell DP, Mani V, Keighley MR, Kingston RD, Record CO, Grace RH, Daniels S, Patterson J, Smith K: A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut 38:229–233, 1996
Friedman LS, Richter JM, Kirkham SE, DeMonaco HJ, May RJ: 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: A randomized, controlled trial. Am J Gastroenterol 81:412–418, 1986
Porro GB, Ardizzone S, Petrillo M, Fasoli A, Molteni P, Imbesi V: Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized, double-blind study. Am J Gastroenterol 90:736–739, 1995
Campieri M, Lanfranchi GA, Bazzocchi G, Brignola C, Sarti F, Franzin G, Battocchia A, Labo G, Dal Monte PR: Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 2:270–271, 1981
Danish 5-ASA Group: Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Dig Dis Sci 32:598–602, 1987
Mulder CJ, Tytgat GN, Wiltink EH, Houthoff HJ: Comparison of 5-aminosalicylic acid (3 g) and prednisolone phosphate sodium enemas (30 mg) in the treatment of distal ulcerative colitis. A prospective, randomized, double-blind trial. Scand J Gastroenterol 23:1005–1008, 1988
Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN: Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 8:549–553, 1996
Lemann M, Galian A, Rutgeerts P, Van Heuverzwijn R, Cortot A, Viteau JM, Elewaut A, Belaiche J, Froguel E, Modigliani R: Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 9:557–562, 1995
Rufle W, Fruhmorgen P, Huber W, Kimmig JM: Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study. (In German) Z Gastroenterol 38:287–293, 2000
Pullan RD, Ganesh S, Mani V, Morris J, Evans BK, Williams GT, Rhodes J: Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: A controlled trial. Gut 34:676–679, 1993
Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A metaanalysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 95:1263–1276, 2000
Kam L, Cohen H, Dooley C, Rubin P, Orchard J: A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol 91:1338–1342, 1996
Powell-Tuck J, MacRae KD, Healy MJ, Lennard-Jones JE, Parkins RA: A defence of the small clinical trial: Evaluation of three gastroenterological studies. Br Med J (Clin Res Ed) 292:599–602, 1986
Campieri M, Paoluzi P, D'Albasio G, Brunetti G, Pera A, Barbara L: Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema. Dig Dis Sci 38:1843–1850, 1993
Campieri M, Corbelli C, Gionchetti P, Brignola C, Belluzzi A, Di Febo G, Zagni P, Brunetti G, Miglioli M, Barbara L: Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci 37:1890–1897, 1992
Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tabanelli GM, Miglioli M, Barbara L: 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin Gastroenterol 10:406–409, 1988
Gionchetti P, Ardizzone S, Benvenuti ME, Bianchi Porro G, Biasco G, Cesari P, D'Albasio G, De Franchis R, Monteleone G, Pallone F, Ranzi T, Trallori G, Valpiani D, Vecchi M, Campieri M: A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: A randomized controlled multicentre trial. Aliment Pharmacol Ther 13:381–388, 1999
Hanauer S, Good LI, Goodman MW, Pizinger RJ, Strum WB, Lyss C, Haber G, Williams CN, Robinson M: Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 95:1749–1754, 2000
D'Arienzo A, Panarese A, D'Armiento FP, Lancia C, Quattrone P, Giannattasio F, Boscaino A, Mazzacca G: 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: A double-blind placebo-controlled clinical trial. Am J Gastroenterol 85:1079–1082, 1990
Biddle WL, Greenberger NJ, Swan JT, McPhee MS, Miner PB, Jr: 5-Aminosalicylic acid enemas: Effective agent in maintaining remission in left-sided ulcerative colitis Gastroenterology 94:1075–1079, 1988 [published erratum appears in Gastroenterology 96(6):1630, 1989]
Andreoli A, Spinella S, Levenstein S, Prantera C: 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis. Ital J Gastroenterol 26:121–125, 1994
Trallori G, Messori A, Scuffi C, Bardazzi G, Silvano R, d'Albasio G, Pacini F: 5-Aminosalicylic acid enemas to maintain remission in left-sided ulcerative colitis: A meta-and economic analysis. J Clin Gastroenterol 20:257–259, 1995
Peppercorn MA: Sulfasalazine, Pharmacology, clinical use, toxicity, and related new drug development. Ann Intern Med 101:377–386, 1984
Rasmussen SN, Lauritsen K, Tage-Jensen U, Nielsen OH, Bytzer P, Jacobsen O, Ladefoged K, Vilien M, Binder V, Rask-Madsen J: 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 22:877–883, 1987
Singleton J: Second trial of mesalamine therapy in the treatment of active Crohn's disease Gastroenterology 107:632–633, 1994 (letter; comment)
Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR: A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 19:278–282, 1994
Gross V, Andus T, Fischbach W, Weber A, Gierend M, Hartmann F, Scholmerich J: Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group. Z Gastroenterol 33:581–584, 1995
Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E: A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group [see comments]. N Engl J Med 339:370–374, 1998
Prantera C, Cottone M, Pallone F, Annese V, Franze A, Cerutti R, Bianchi Porro G: Mesalamine in the treatment of mild to moderate active Crohn's ileitis: Results of a randomized, multicenter trial. Gastroenterology 116:521–526, 1999
Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, Notteghem B, Mary JY: A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 94:674–678, 1999
Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, Krawitt EL: Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial. Pentasa Crohn's Disease Study Group [see comments]. Gastroenterology 104:1293–1301, 1993
Singleton JW, Hanauer S, Robinson M: Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci 40:931–935, 1995
Tromm A, Griga T, May B: Oral mesalazine for the treatment of Crohn's disease: Clinical efficacy with respect to pharmacokinetic properties. Hepatogastroenterology 46:3124–3135, 1999
Steinhart AH, Hemphill D, Greenberg GR: Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: A meta-analysis. Am J Gastroenterol 89:2116–2124, 1994
Arber N, Odes HS, Fireman Z, Lavie A, Broide E, Bujanover Y, Becker S, Pomerantz I, Moshkowitz M, Patz J: A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. J Clin Gastroenterol 20:203–206, 1995
International Mesalazine Study Group: Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ther 4:55–64, 1990
Brignola C, Iannone P, Pasquali S, Campieri M, Gionchetti P, Belluzzi A, Basso O, Miglioli M, Barbara L: Placebocontrolled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci 37:29–32, 1992
Gendre JP, Mary JY, Florent C, Modigliani R, Colombel JF, Soule JC, Galmiche JP, Lerebours E, Descos L, Viteau JM: Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: A multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID) [see comments]. Gastroenterology 104:435–439, 1993
Sutherland LR, Martin F, Bailey RJ, Fedorak RN, Poleski M, Dallaire C, Rossman R, Saibil F, Lariviere L: A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 112:1069–1077, 1997
Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, Duclos B, Soule JC, Gendre JP, Galmiche JP, Danne O, Cadiot G, Lamouliatte H, Belaiche J, Mary JY: Mesalamine in Crohn's disease with steroid-induced remission: Effect on steriod withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 110:688–693, 1996
Thomson AB, Wright JP, Vatn M, Bailey RJ, Rachmilewitz D, Adler M, Wilson-Lynch KA: Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther 9:673–683, 1995
de Franchis R, Omodei P, Ranzi T, Brignola C, Rocca R, Prada A, Pera A, Vecchi M, Del Piano M, Ferrara A, Belloli C, Piodi L, Framarin L, Astegiano M, Riccioli FA, Meucci G: Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. Aliment Pharmacol Ther 11:845–852, 1997
Prantera C, Pallone F, Brunetti G, Cottone M, Miglioli M: Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group [see comments]. Gastroenterology 103:363–368, 1992
Achkar JP, Hanauer SB: Medical therapy to reduce postoperative Crohn's disease recurrence. Am J Gastroenterol 95:1139–1146, 2000
Cammà C, Giunta M, Rosselli M, Cottone M: Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables. Gastroenterology 113:1465–1473, 1997
McLeod RS, Wolff BG, Steinhart AH, Carryer PW, O'Rourke K, Andrews DF, Blair JE, Cangemi JR, Cohen Z, Cullen JB: Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease [see comments]. Gastroenterology 109:404–413, 1995
Brignola C, Cottone M, Pera A, Ardizzone S, Scribano ML, De Franchis R, D'Arienzo A, D'Albasio G, Pennestri D: Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology 108:345–349, 1995
Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, Petritsch W, Raithel M, Hoffmann R, Gross V, Plauth M, Staun M, Nesje LB: Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI [see comments] Gastroenterology 2000; 118:264–273, [published erratum appears in Gastroenterology 119(1):280, 2000]
Florent C, Cortot A, Quandale P, Sahmound T, Modigliani R, Sarfaty E, Valleur P, Dupas JL, Daurat M, Faucheron JL, Lerebours E, Michot F, Belaiche J, Jacquet N, Soule JC, Rothman N, Gendre JP, Malafosse M: Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Eur J Gastroenterol Hepatol 8:229–233, 1996
Caprilli R, Andreoli A, Capurso L, Corrao G, D'Albasio G, Gioieni A, Assuero Lanfranchi G, Paladini I, Pallone F, Ponti V: Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 8:35–43, 1994
Cottone M, Camma C: Mesalamine and relapse prevention in Crohn's disease [letter]. Gastroenterology 119:597, 2000
Hanauer SB, Krawitt EL, Robinson M, Rick GG, Safdi MA: Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group [see comments]. Am J Gastroenterol 88:1343–1351, 1993
Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C, d'Albasio G, De Simone G, Martini N: Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 89:692–698, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gisbert, J.P., Gomollón, F., Maté, J. et al. REVIEW: Role of 5-Aminosalicylic Acid (5-ASA) in Treatment of Inflammatory Bowel Disease: A Systemic Review. Dig Dis Sci 47, 471–488 (2002). https://doi.org/10.1023/A:1017987229718
Issue Date:
DOI: https://doi.org/10.1023/A:1017987229718